Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.

Molecular cancer therapeutics - 1 Jan 2021

Abusarah Jamilah, Cui Yun, El-Hachem Nehme, El-Kadiry Abed El-Hakim, Hammond-Martel Ian, Wurtele Hugo, Beaudry Annie, Raynal Noël J-M, Robert Francis, Pelletier Jerry, Jankovic Maja, Mercier Francois, Kamyabiazar Samaneh, Annabi Borhane, Rafei Moutih

Abstract excerpt

We report the discovery, via a unique high-throughput screening strategy, of a novel bioactive anticancer compound: Thiol Alkylating Compound Inducing Massive Apoptosis (TACIMA)-218. We demonstrate that this molecule engenders apoptotic cell death in genetically diverse murine and human cancer cell lines, irrespective of their p53 status, while sparing normal cells. TACIMA-218 causes oxidative stress in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylation
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoplasmic Reticulum Stress

Share to Glycolysis

Share to Heme Oxygenase-1

Share to NF-E2-Related Factor 2

Share to Oxidants

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 33087510
DOI: 10.1158/1535-7163.MCT-20-0333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.PMID 33087510Read ↗

Selective killing of cancer cells by a small molecule targeting the stress response to ROS.Semantic proximity Read ↗

Programmed cell death, redox imbalance, and cancer therapeuticsSemantic proximity Read ↗

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008Semantic proximity Read ↗

Oxidative Stress in Cancer Therapy: Friend or Enemy?Semantic proximity Read ↗

Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.Semantic proximity Read ↗

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read ↗

Immunogenic cell death-inducing metal complexes: From the benchtop to the clinicSemantic proximity Read ↗

Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.Semantic proximity Read ↗

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.Semantic proximity Read ↗

Targeting Cancer with Phytochemicals via Their Fine Tuning of the Cell Survival Signaling PathwaysSemantic proximity Read ↗

Cancer cell killing via ROS: To increase or decrease, that is the questionSemantic proximity Read ↗

A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.